Your browser doesn't support javascript.
loading
CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors.
Rosenblum, Joshua M; Shimoda, Naohiko; Schenk, Austin D; Zhang, Howard; Kish, Danielle D; Keslar, Karen; Farber, Joshua M; Fairchild, Robert L.
Afiliación
  • Rosenblum JM; Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA. jmr55@case.edu
J Immunol ; 184(7): 3450-60, 2010 Apr 01.
Article en En | MEDLINE | ID: mdl-20194716
ABSTRACT
Donor Ag-reactive CD4 and CD8 T cell production of IFN-gamma is a principal effector mechanism promoting tissue injury during allograft rejection. The CXCR3-binding chemokines CXCL9 and CXCL10 recruit donor-reactive T cells to the allograft, but their role during the priming of donor-reactive T cells to effector function is unknown. Using a murine model of MHC-mismatched cardiac transplantation, we investigated the influence of CXCL9 and CXCL10 during donor-reactive T cell priming. In allograft recipient spleens, CXCL9 and CXCL10 were expressed as early as 24 h posttransplant and increased with similar kinetics, concurrently with CXCR3 expression on T cells. CXCL9, but not CXCL10, expression required NK cell production of IFN-gamma. The absence of CXCL9 in donor allografts, recipients, or both significantly decreased the frequency of donor-reactive CD8 T cells producing IFN-gamma and increased the frequency of donor-reactive CD8 T cells producing IL-17A. In contrast, the absence of CXCL10 increased the frequency of IFN-gamma-producing CD8 T cells in a CXCL9-dependent manner. These data provide novel evidence that donor-reactive CD8 T cells use the CXCR3 chemokine axis as a costimulation pathway during priming to allografts where CXCL9 promotes the development of IFN-gamma-producing CD8 T cells, and CXCL10 antagonizes this skewing.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Activación de Linfocitos / Linfocitos T / Quimiocina CXCL9 / Quimiocina CXCL10 / Rechazo de Injerto Límite: Animals Idioma: En Revista: J Immunol Año: 2010 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Activación de Linfocitos / Linfocitos T / Quimiocina CXCL9 / Quimiocina CXCL10 / Rechazo de Injerto Límite: Animals Idioma: En Revista: J Immunol Año: 2010 Tipo del documento: Article País de afiliación: Estados Unidos